3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
20
Breast Neoplasms
11
Prostatic Neoplasms
10
Neoplasms
7
Neoplasm Metastasis
7
Fallopian Tube Neoplasms
7
Pancreatic Neoplasms
6
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Lung Neoplasms
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
SCLC,Extensive Stage
1
Recurrence
1
Rectal Neoplasms
1
Prostate Adenocarcinoma
1
Interventions
pembrolizumab
27
Oxaliplatin
24
Paclitaxel
22
Fluorouracil
21
Carboplatin
18
Leucovorin
16
Cisplatin
16
Capecitabine
16
Radiotherapy
15
Nivolumab
12
Drug Therapy
12
Radiation
10
Trastuzumab
9
Surgical Procedures, Operative
9
Immunotherapy
8
Magnetic Resonance Spectroscopy
7
Esophagectomy
7
Blood Specimen Collection
7
Taxes
6
durvalumab
5
Surveys and Questionnaires
5
Specimen Handling
5
Radiotherapy, Intensity-Modulated
5
Irinotecan
5
Immune Checkpoint Inhibitors
5
Docetaxel
5
Bevacizumab
5
tislelizumab
4
Ramucirumab
4
Fluorodeoxyglucose F18
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
niraparib
×
1 year
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts